F. Da Roit

Ofatumumab Is More Efficient than Rituximab in Lysing B Chronic Lymphocytic Leukemia Cells in Whole Blood and in Combination with Chemotherapy

M. Introna, A. Rambaldi, Alessandro Rambaldi, 2013, The Journal of Immunology.

Glycoengineered CD20 antibody obinutuzumab activates neutrophils and mediates phagocytosis through CD16B more efficiently than rituximab.

C. Klein, J. Leusen, M. Introna, 2013, Blood.

Clinical grade expansion of MSCs.

R. Valgardsdottir, M. Introna, J. Golay, 2015, Immunology letters.